The Egyptian HCV Control Program
|
|
- Archibald McDaniel
- 6 years ago
- Views:
Transcription
1 The Egyptian HCV Control Program Wahid Doss, MD Professor of Hepatology,Cairo University Head, National Committee for control of Viral Hepatitis, Egypt
2 Disclosure speaker interests Disclosure of speaker interest Conducted clinical trials for Gilead, Jansen, Abbvie
3 Global Prevalence of Hepatitis C
4 Countries Responsible for 80% of Global Infections Gower, E., Estes C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus, Journal of Hepatology (2014)
5 HCV burden in Egypt is the highest in the world a unique challenge HCV seroprevalence in Egypt in 2015 estimated to be 4.7% overall; years 7% National epidemic with social, economic and political implications. Leading public health challenge. Caused initially by extensive iatrogenic transmission during the era of parenteral-antischistosomal-therapy mass-treatment campaigns. > 90% GT 4. MOH estimates 150, ,000 patients newly infected per year.
6 Current Disease Burden Estimates based on the 2015 Demographic and Health Survey (EDHS)
7 Incidence Current Disease Burden in Egypt Egyptian data /1,000 = 150, ,000 new cases/year Strongest predictor: Anti-HCV+ family member (5.8/1,000 vs 1.0/1,000) 67% of sero-converters <20 years Highest incidence (14.1/1,000 PY) in children <10 years living in households with an anti-hcv+ parent Computer simulation: 2 6.6/1,000 = 514,000 new cases per year Europe: 0.08/1,000 in Mohamed MK, et al. Hepatology. 2005;42:683-7; 2. Miller FD & Abu-Raddad LJ. Proc Natl Acad Sci USA. 2010;107(33):
8 Burden of HBV and HCV in Egypt Over 20 Years HCV 15-22% -HBsAg 4.5% -HBcAb 22.5% 2008 (EDHS) -HCV RNA 9.8% (Age yrs) 2015 (EDHS) -HCV RNA 7% (Age yrs) -HCV-RNA 4.4% (Age 1-59 yrs) -HBsAg 1% -HBcAb 9.9% (1-59 yrs)
9 Egyptian Government tackling HCV problem Until 2006 Egypt did not have a comprehensive national program for control of HCV: No large nationwide survey for the disease, accurate prevelance data unavailable Government did not cover HCV therapy No national guidelines for treatment Limited infection control program
10 National Committee for Control of Viral Hepatitis Established in 2006 Targets National Survey & Burden of Disease Develop a National Strategy Treatment Program Prevention Awareness Infection control Clinical Research Management of advanced liver disease (ALD) Outcome HCV testing integrated in DHS survey 2008 and 2015 National Strategy: Plan of Action: Successful treatment program IC remains fragmented Hepatitis research units Over 15 liver transplant centres
11 Developments 2011 through 2016 Treatment Clinical trials with DAAs (GT4) Negotiations & registration of Sofosbuvir 2014 Web-based national patient enrolment for DAA treatment (>1.5 million so far) First patient started treatment Oct 16 th 2014 Other DAAs introduced in 2015 and 2016 Prevention Action plan launched Oct 2014 Components (Surveillance, IC, Blood safety, Vaccination, IEC, Screening, care and treatment
12 Governorates Treatment centers in Egypt (55) Treatment Centers In the villages of the Nile Delta, half of all men older than 50 are infected with hepatitis C.Credit David Degner for The New York Times
13 Flow Chart for Treatment Enrollment National Program Patients register on website portal Management review (medical and administrative) for approval Patient gets approval for treatment Appointment (24 hrs later) & list of required tests Data Entry from centers (NNTC) Patient starts treatment Blood tests & Abdominal US Evaluation clinic & Enrolment FUP data in NNTC
14 Web-Based Registration System (Sept 2014) General information for the patients
15 Fields to be filled for registry online National ID Full name Mother name governorate Mobile no
16 Appointment given after 24 hrs of registry National ID
17 Appointment paper to be printed Instructions for the patients on their first visit Place of appointment Time of appointment Date of appointment National ID Name
18 List of labs required to be available on first visit, performed for free
19 FAQs
20 Number of Patients registered online 1,5 1 8,3 2 5
21 Number of Portal registry First 3 days Nov
22 Characteristics of registered patients Age groups Male/ Female >60 yrs % yrs % yrs %14 %37.81 % yrs % yrs %26 Females Males
23 New sheet m
24 New sheet
25 New sheet
26 New sheet
27 New sheet
28 New sheet
29 New sheet
30 New sheet
31 Chronology of Treatment Protocols Implemented by the National Program Date Implmented Protocol Inclusion criteria PegIFN-RBV F1-F3 patients October 2014-May 2015 Sofosbuvir-PegIFN-RBV F3,F4 ;IFN tolerant Sofosbuvir-RBV F3,F4 ;IFN intolerant up to Child B 8 (down to 7) May 2015-November 2015 Sofosbuvir-PegIFN-RBV F0-F4, normal synthetic function Sofosbuvir-Simeprevir F0-F4, impaired synthetic function up to Child A6 November 2015 Two DAAs ± RBV F0-F4, impaired synthetic function up to B7. Higher Child in special centers
32 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Timeline for treatment protocols Sof/IFN/RBV SOF/RBV SOF/SIM SOF/DAC SOF/DAC/RBV Generic Sofosbuvir
33 The total number of patients treated in Egypt (October 14 November 16) Patients % % % % NCCVH affiliated centers health insurance Cash Military & other hospitals
34 *Details of treatment outcome in DAA (IFN/SOF/RBV) protocol 450; 3% 366; 3% 537; 4% 11907; 90% SVR relapser NR DC Undefine d; 43 Hematolo gical; 36 Renal impairment ; 1 LF; 20 *for first group of patients whose outcome available= patients
35 *Details of treatment outcome in DAA (SOF/RBV) protocol 168; 2% 766; 10% 984; 12% SVR relapser NR Undefine d; 33 Hematolo gical; 30 Renal impairment ; ; 76% DC LF; 36 % *for first group of patients whose outcome available= 7958 patients
36 *Details of treatment outcome in DAA (SOF/SIM) protocol 129; 2% 156; 3% 136; 2% 5739; 93% SVR relapser NR DC Undefine d; 28 Hematolo gical; 3 LF; 65 HCC; 4 % *for first group of patients whose outcome available= 6160 patients
37 *Details of treatment outcome in DAA (SOF/DAC) protocol 108; 1% 259; 3% 100; 1% 9653; 95% SVR relapser NR DC Undefine d; 76 Hematolo gical; 5 HCC; 4 LF; 15 % *for first group of patients whose outcome available= patients
38 *Details of treatment outcome in DAA (SOF/DAC/RBV) protocol 89; 1% 183; 2% 166; 2% 7820; 95% SVR relapser NR DC Undefine d; 76 Hematolo gical; 5 HCC; 3 LF; 24 % *for first group of patients whose outcome available= 8258 patients
39 Percent Summary SVR for each treatment protocol 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 90% 93% 95% 95% 76% SOF/IFN/RBV SOF/RBV SOF/SIM SOF/DAC SOF/DAC/RBV
40 Economic Burden HCV infection is a huge economic burden in Egypt Direct healthcare cost US$ 670 Mln Indirect economic impact of disability US$ 3.7 Bln Close to 1.8% of the GDP (Similar to DM and CVD cost in the US) Intangible costs to society and families not assessed Treatment of large numbers of patients with effective therapy is the best option for control Curing a patient saves ~ US$ 10,000 for the next 15 years Preventing a case saves ~ US$ 20,000 for the next 40 years without active prevention there will be 1Mln more cases in 2030 Estes C, et al. Alim. Pharm. Ther. 2015
41 HCV Control in Egypt : Challenges Generics: - Quality assurance - Voluntary licensing - Prequalification Lack of legislations Political competing priorities Lack of patient support groups Tailored protocols Access - Remote areas - Shorter duration & less visits - Children Screening - Rapid tests? - Compulsory testing? - Repeat Testing? Quality Assurance and monitoring Stigma - Adults - Children
42 HCV Control in Egypt : Constraints Fragmentation of health care delivery system Different health sectors (MoHP; MoHE; HIO; private; military; police and others ) poor coordination However, multi-sectoral VH action plan. Financial constraints (no specified budget for prevention). Address lessons & gaps for strengthening of treatment program (only 45% report SVR, data incomplete)
43 NCCVH (2006-Current) Prof Wahid Doss (Chair) Prof Gamal Esmat Prof Moustafa K Mohamed (late) Prof Manal H El-Sayed Dr Nasr El-Sayed (Former MoH) Dr Arnaud Fontanet Recent Members Prof Magdy El-Serafy Prof Ayman Yousry Prof Ashraf Omar Prof Wagida Anwar Prof Maissa Shawky Dr Amr Kandil (MoH) Acknowledgement WHO-TAG for Prevention, Control and Treatment of Viral Hepatitis (June 2011) Dr. Arnaud Fontanet (Chair) Prof Manal H El-Sayed (Vice Chair) Dr Francisco Averhoff Dr Steven Wieresma Prof Gamal Esmat Prof Wahid Doss Prof Mohsen Gadallah Dr Jaoad Mahjour Ad hoc International Experts Prof Mark Thursz Dr David Goldberg Special Acknowledgement for Efforts in Developmen and Printing of PoA Mr Henk Bekedam Dr Nasr Tantawy Ms Amy Kolwaite Ms Adeline Berner WHO country office team Dr Sahar Shorbagy (MoH) 12/5/
44
Access to Innovation: Hepatitis C and the Egyptian National Experience
Access to Innovation: Hepatitis C and the Egyptian National Experience Manal El Sayed Professor of Pediatrics Ain Shams University NCCVH, MOH (EGYPT) Stepwise Solution for LMIC (Real Life Experience) Data
More informationNational Strategy for Control and Prevention of Viral Hepatitis: An Update
National Strategy for Control and Prevention of Viral Hepatitis: An Update Manal Hamdy El-Sayed Professor of Pediatrics Ain Shams University National Committee for Control for Viral Hepatitis Disclosure
More informationHCV Elimination in Egypt
HCV Elimination in Egypt Prof. Gamal Esmat Prof. Hepatology &Ex. Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Disclosure Slide Advisory
More informationAccess to HCV treatment in Egypt
Access to HCV treatment in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution
More informationReal-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C
Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C Prof. Gamal Esmat Prof. Hepatology & Vice President of Cairo
More informationIFN IFN IFN/RBV IFN/RBV
Medicaid and Viral Hepatitis Treatment in Kentucky Kentucky 5th Annual Viral Hepatitis Conference Ending the Epidemic: The Role of Professionals in Hepatitis Elimination Disclosure Jens Rosenau has received
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatitis and HIV Co-Infection: Situation in Ukraine.
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV Hepatitis and HIV Co-Infection: Situation in Ukraine. Pavlo Skala Associate Director: Policy & Partnership Ukraine
More informationHEPATITIS C ELIMINATION IN GREECE
HEPATITIS C ELIMINATION IN GREECE ANGELOS HATZAKIS Professor of Epidemiology & Preventive Medicine Athens University Medical School Co-Chair, Hepatitis B & C Public Policy Association London, UK June 5,
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationEliminating Hepatitis C from Egypt: 2017 Update on Current Trends and Policy Recommendations. program. Public Disclosure Authorized
Eliminating Hepatitis C from Egypt: 2017 Update on Current Trends and Policy Recommendations Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized program Public Disclosure
More informationRisk Factors for Hepatitis C Infection in a National Adult Population: Evidence from the 2008 Egypt DHS
Risk Factors for Hepatitis C Infection in a National Adult Population: Evidence from the 2008 Egypt DHS Jasbir Sangha*, Ann Way*, Fatma El-Zanaty, and Nasr El-Sayed *ICF Macro, Demographic and Health Surveys,
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationA Nation-wide Investigation of Real-World Community Effectiveness in HCV Treatment for Policy-making Toward Elimination of HCV by 2030 in Taiwan
A Nation-wide Investigation of Real-World Community Effectiveness in HCV Treatment for Policy-making Toward Elimination of HCV by 2030 in Taiwan MING-LUNG YU Distinguished Professor, Hepatobiliary Division,
More informationA national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD
A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre
More informationFINANCIAL DISCLOSURE
FINANCIAL DISCLOSURE People who work at NIH only dream about having financial disclosures Wait, this just in. The US government has now banned dreaming CRITICAL NON-FINANCIAL DISCLOSURES Nothing I say
More informationGenotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute
Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute Paris, January 12, 215 Disclosures Investigator, speaker, and advisory board member for: Roche, MSD, BMS, Gilead, Janssen,
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationEconomic and societal impact of direct-acting antiviral therapy in Hepatitis C Zoltán Kaló
Economic and societal impact of directacting antiviral therapy in Hepatitis C Zoltán Kaló Professor of Health Economics ISPOR 19th Annual European Congress November 2 nd 2016 ATHCV16099925102016 Concerns
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationHepatitis C No Barriers to Cure
2018 Digestive Diseases Conference Kansas Hepatitis C No Barriers to Cure Dr. Mauricio Lisker Melman Professor of Medicine Director Hepatology Program Division of Gastroenterology Disclosure The following
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More informationRolling up HCV treatment programs for PWIDs in Ukraine
Rolling up HCV treatment programs for PWIDs in Ukraine www.aph.or g.ua Ludmila Maistat Alliance for Public Health VHPB Meeting, Highlight undeserved groups for screening, prevention and treatment of viral
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD
ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD 17 May 2018 Bucharest, Romania Organisers Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe
More informationTreatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017
Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationDeveloping National Plans in Europe Spain
Developing National Plans in Europe Spain Rafael Esteban Hospital Universitario Valle Hebron. Barcelona, Spain September 2015 Frankfurt Financial Disclosure Statement Consultant for: AbbVie, Bristol-Myers
More informationSeasonality of influenza activity in Hong Kong and its association with meteorological variations
Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific
More informationGlobal strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators
Global strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators Antons Mozalevskis WHO Regional Office for Europe EMCDDA DRID National Expert Meeting Lisbon, 6
More informationAngelos Hatzakis. 10th Paris Hepatology Conference
Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationMonitoring hepatitis C treatment uptake in Australia
Monitoring hepatitis C treatment uptake in Australia Issue #7 July 217 1 Initiations of new treatment for chronic hepatitis C in 216 An estimated 32,4 individuals initiated direct acting antiviral (DAA)
More informationAn overview of the Hepatitis C control plan in Qatar
An overview of the Hepatitis C control plan in Qatar Moutaz Derbala 1, Elmoubasher Abd Farag 2, Hamad E. Al Romaihi 2, Saad Al Kaabi 1, Mohamed Al Thani 2, Elham El Sayed 3, Aliaa Amer 1 and Sayed Himatt
More informationHEPATITIS C TREATMENT UPDATE
HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%
More informationOne State s Perspective on the Management of Hepatitis C Drugs. February 27, 2015 Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist
One State s Perspective on the Management of Hepatitis C Drugs Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist Statement of Disclosure I have no relevant financial relationships that would be
More informationInstitute of Quality Leadership AMGA
Institute of Quality Leadership AMGA Ajay Sahajpal, MD Director Abdominal Transplant and Hepatobiliary Program Bradley Kruger, VP Operations ASLMC Laura Spurr, Director Clinical Transformation and Operations
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationEgypt Success Story In Combating Avian Influenza
Egypt Success Story In Combating Avian Influenza Wild bird situation Approximately 4 millions migratory birds pass over Egypt. About 500,000 migratory birds spend a period of time in 35 Wetland Areas Highly
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationCASE STUDY Improving the quality of VMMC services at Mangochi, Mzimba North, and Nkhotakota District Hospitals in Malawi
CASE STUDY Improving the quality of VMMC services at Mangochi, Mzimba North, and Nkhotakota District Hospitals in Malawi With support from United States Agency for International Development (USAID), multi-sectoral
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationPlacing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat
Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat John W. Ward, M.D Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD &
More informationHomie Razavi. CDA Foundation Polaris Observatory. From Economic Analysis to Financial Dialogue
Homie Razavi CDA Foundation Polaris Observatory From Economic Analysis to Financial Dialogue The CDA Foundation Accelerate hepatitis B and C elimination through verified data, modeling, intervention strategies,
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationViral Hepatitis Prevention Board
Viral Hepatitis Prevention Board Prevention and control of viral hepatitis in Albania and neighbouring countries: lessons learnt and the way forward TIRANA, ALBANIA 27-28 October 2016 Objectives To provide
More informationHealth Equity Workgroup. January 18, 2018
Health Equity Workgroup January 18, 2018 Health Equity Workgroup Co-Chairs Fleda Mask Jackson, PhD Founder, Save 100 Babies President and CEO, Majaica, LLC University Affiliate, Columbia University Arthur
More informationNumbers HCV and HIV Epidemiology in the US
By The Numbers HCV and HIV Epidemiology in the US Coinfection Fridays Session 1 18 January 2019 Christopher B. Hurt, MD Associate Professor of Medicine Co-Director, North Carolina AIDS Training & Education
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationHepatitis B and Hepatitis C Virus in non-liver Transplant Recipients. Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London
Hepatitis B and Hepatitis C Virus in non-liver Transplant Recipients Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London Financial Disclosures Research Grants Merck, Gilead, Abbvie,
More informationProgress in maternal and child health: Uzbekistan and WHO European Region
Progress in maternal and child health: Uzbekistan and WHO European Region The National Model of Maternal and Child Health Protection in Uzbekistan: Zsuzsanna Jakab WHO Regional Director for Europe UZBEKISTAN
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni)
Hepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni) Prof. Dr. Markus Cornberg Klinik für Gastroenterologie, Hepatologie und Endokrinologie Antalya, 13.05.2016 Markus Cornberg, Hannover
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationIdentification and management of chronic viral hepatitis in Russia
Technical Viral Hepatitis Prevention Board Meeting IDENTIFICATION AND MANAGEMENT OF PERSONS WITH CHRONIC VIRAL HEPATITIS IN EUROPE Budapest, Hungary, March 18-19, 21 Identification and management of chronic
More informationThe American University in Cairo. School of Global Affairs and Public Policy
The American University in Cairo School of Global Affairs and Public Policy ESTIMATING ECONOMIC AND EPIDEMIOLOGICAL BURDEN OF HEPATITIS C IN EGYPT, 2015-2025 A Thesis Submitted to the Public Policy and
More informationWill HCV therapies deliver global impact? Professor Greg Dore
Will HCV therapies deliver global impact? Professor Greg Dore Disclosures Gregory Dore has received research grants awarded to his institution from Gilead, Bristol Myers Squibb, Abbvie, Merck, and Janssen;
More informationMinistry of Health and Population Preventive and Endemic Diseases Sector Epidemiology and Disease Surveillance Unit (ESU)
Ministry of Health and Population Preventive and Endemic Diseases Sector Epidemiology and Disease Surveillance Unit (ESU) Experience Gained From Avian Flu Outbreaks in Egypt Early Detection Of Cases, Female
More informationThe Egyptian Plan to Cure HCV
The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationWe have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci Pressures for new vaccine introduction. International institutions. Vaccine manufacturers National
More informationTreatment and Access to Drugs
Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,
More informationHIV/hepatitis co-infection. Christoph Boesecke Department of Medicine I University Hospital Bonn Germany
HIV/hepatitis co-infection Christoph Boesecke Department of Medicine I University Hospital Bonn Germany Clinical Management and Treatment of HBV and HCV Co-infection in HIVpositive Persons Hepatitis B
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationHEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?
HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? Ganiyat Kikelomo OYELEKE FMCP Hepatologist & Gastroenterologist Lagos University Teaching Hospital, Nigeria. INTEREST 2018, KIGALI CONFERENCE
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationDr Emma Thomson. University of Glasgow Centre for Virus Research, UK
Dr Emma Thomson University of Glasgow Centre for Virus Research, UK Dr Emma Thomson University of Glasgow Centre for Virus Research, UK Speaker Name Emma Thomson COMPETING INTEREST OF FINANCIAL VALUE >
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationEast London Community Kidney Service
East London Community Kidney Service Sally Hull, Neil Ashman, Sec Hoong, Nicola Thomas, Helen Rainey April 2017 Haemodialysis/million population What is the Problem? Fast rising ESRD rates in East London
More informationMalaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018
Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision Mary J Hamel, WHO MPAC, 11 April 2018 MVIP update Background to MVIP MVIP Updates Regulatory Vaccine introduction
More informationUpdate on Pandemic H1N1 2009: Oman
Update on Pandemic H1N1 29: Oman Dr Idris Al-Abaidani, MoH Websites: who.int, ecdc.europa.eu, cdc.gov, moh.gov.om 212 countries reported cases and 15921 deaths Seasonal Flu & H1N1 29 Flu *The reported
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationGetting to Zero in California: Integration of HIV Prevention and Surveillance
Getting to Zero in California: Integration of HIV Prevention and Surveillance Steve Gibson, MSW and Deanna Sykes, PhD CDPH, Office of AIDS November 27, 2017 Learning Objectives Understand reasons for integrated
More informationGlobal and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.
Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable
More informationGeneric HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK
Generic HCV DAAs Economics and sustainability Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK Sunday, 23rd July 2017 Paris, France www.iasociety.org HCV DAAs can be made very
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationPast Influenza Pandemics
Outline Background Pandemic Response in Oman Pre Pandemic Phase Pandemic Phase Post Pandemic Phase p(h1n1) vaccination strategy Cost of Pandemic Impact on Health System Lessons learnt Conclusions 2 Oman..
More informationPriority setting: the case of new drugs. Parallel session: Universal Health Coverage, costing and prioritization
Priority setting: the case of new drugs Parallel session: Universal Health Coverage, costing and prioritization Dr Jeremy Lauer Health Systems Governance and Financing 1 Department of Health Systems Governance
More informationHCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo
HCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo antonio.craxi@unipa.it Key factors in deciding to treat or wait Patient factors Urgency
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationThe birthof the Dutch National hepatitis plan
Improving Mental Health by Sharing Knowledge The birthof the Dutch National hepatitis plan A success story in many parts Esther Croes MD PhD WHO: framework for global action In 2012 the WHO stated: viral
More informationSection 9: Tackling the Hepatitis C epidemic: a global landscape
Section 9: Tackling the Hepatitis C epidemic: a global landscape Céline Grillon (Médecins du Monde) Training Hepatitis C and HR for PWUD, 19 th -24 th Sept. 2016, Nairobi, Kenya Learning objective of the
More informationDisclosures. Learning Objectives. Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement
Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement Alix Casler, M.D., F.A.A.P. Medical Director of Pediatrics, Orlando Health Physician Associates
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More information